359 related articles for article (PubMed ID: 29028645)
1. An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer.
Nicholson KJ; Yip L
Curr Opin Oncol; 2018 Jan; 30(1):8-15. PubMed ID: 29028645
[TBL] [Abstract][Full Text] [Related]
2. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
3. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
Bose S; Sacks W; Walts AE
Adv Anat Pathol; 2019 Mar; 26(2):114-123. PubMed ID: 30664001
[TBL] [Abstract][Full Text] [Related]
4. Role of Ancillary Techniques in Thyroid Cytology Specimens.
Nishino M; Krane JF
Acta Cytol; 2020; 64(1-2):40-51. PubMed ID: 30947167
[TBL] [Abstract][Full Text] [Related]
5. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
6. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
[TBL] [Abstract][Full Text] [Related]
7. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
Nishino M; Nikiforova M
Arch Pathol Lab Med; 2018 Apr; 142(4):446-457. PubMed ID: 29336606
[TBL] [Abstract][Full Text] [Related]
8. Molecular Testing of Thyroid Nodules: A Review of Current Available Tests for Fine-Needle Aspiration Specimens.
Zhang M; Lin O
Arch Pathol Lab Med; 2016 Dec; 140(12):1338-1344. PubMed ID: 27557410
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Indeterminate Thyroid Nodules Managed Nonoperatively after Molecular Testing.
Zhu CY; Donangelo I; Gupta D; Nguyen DT; Ochoa JE; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1240-e1247. PubMed ID: 33394039
[TBL] [Abstract][Full Text] [Related]
11. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.
Babazadeh NT; Sinclair TJ; Krishnamurthy V; Jin J; Heiden KB; Shin J; Berber E; Siperstein A
Surgery; 2022 Jan; 171(1):155-159. PubMed ID: 34924179
[TBL] [Abstract][Full Text] [Related]
12. Decision Making in Indeterminate Thyroid Nodules and the Role of Molecular Testing.
Mitchell J; Yip L
Surg Clin North Am; 2019 Aug; 99(4):587-598. PubMed ID: 31255193
[TBL] [Abstract][Full Text] [Related]
13. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
14. Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment.
Yip L; Sosa JA
JAMA Surg; 2016 Jul; 151(7):663-70. PubMed ID: 27223483
[TBL] [Abstract][Full Text] [Related]
15. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
16. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
[TBL] [Abstract][Full Text] [Related]
18. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.
Chin PD; Zhu CY; Sajed DP; Fishbein GA; Yeh MW; Leung AM; Livhits MJ
Endocr Pathol; 2020 Dec; 31(4):377-384. PubMed ID: 32671653
[TBL] [Abstract][Full Text] [Related]
19. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
[No Abstract] [Full Text] [Related]
20. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]